20:53 , Mar 20, 2019 |  BC Innovations  |  Translation in Brief

Sangamo’s ZFN linkers finger new options

Sangamo is using new linkers to expand the structural variety of the ZFNs it designs and increase the odds of finding ZFNs with high editing efficiency and specificity for their targets. Conventional zinc finger nucleases...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
17:56 , Jan 22, 2019 |  BC Extra  |  Company News

Bosley leaving Editas as CRISPR company moves toward clinic

Editas Medicine Inc. (NASDAQ:EDIT) said Katrine Bosley is stepping down as president and CEO, effective March 1. Cynthia Collins, a director since December, will be interim CEO while the gene editing company searches for a...
20:08 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Editas to enter clinic with in vivo CRISPR therapy

Editas Medicine Inc. (NASDAQ:EDIT) plans to begin a Phase I/II trial of its CRISPR therapeutic EDIT-101 to treat Leber congenital amaurosis type 10 (LCA10) after FDA cleared its IND. EDIT-101 would be the first in...
20:54 , Nov 30, 2018 |  BC Extra  |  Clinical News

Editas to enter clinic with in vivo CRISPR therapy

Editas Medicine Inc. (NASDAQ:EDIT) plans to begin a Phase I/II trial of its CRISPR therapeutic EDIT-101 to treat Leber congenital amaurosis type 10 (LCA10) after FDA cleared its IND. EDIT-101 would be the first in...
22:45 , Sep 13, 2018 |  BC Week In Review  |  Financial News

ProQR raises $90.6M in upsized offering

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $104.1 million on Sept. 11 through the sale of 6.6 million shares at $15.75 in a bumped-up follow-on underwritten by Citigroup, Evercore ISI, RBC Capital Markets, H.C. Wainwright and Chardan....
17:36 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

Keeping CRISPR on target

Editas Medicine Inc. (NASDAQ:EDIT) has developed an in silico model of Staphylococcus aureus Cas9 (SaCas9) gene editing to help it select guide RNA sequences with minimal risk of off-target effects. Editas’ lead candidate EDIT-101 is...
18:14 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

ProQR planning pivotal trial of vision loss candidate

ProQR Therapeutics N.V. (NASDAQ:PRQR) said it plans to start the pivotal Phase II/III ILLUMINATE trial of QR-110 next half to treat Leber congenital amaurosis type 10 (LCA10) caused by the p.Cys998X mutation in the centrosomal...
18:05 , Sep 7, 2018 |  BC Week In Review  |  Financial News

ProQR raises $90.6M in upsized offering

RNA therapy company ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $90.6 million on Sept. 7 through the sale of 5.8 million shares at $15.75 in a bumped-up follow-on underwritten by Citigroup, Evercore ISI, RBC Capital Markets, H.C....
17:59 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Vertex becomes first U.S. company to enter clinic with CRISPR therapy

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and partner CRISPR Therapeutics AG (NASDAQ:CRSP) have begun enrolling patients in the first U.S. company-sponsored trial using CRISPR/Cas9 editing. The European Phase I/II trial is evaluating CTX001, which comprises autologous CRISPR-modified...